Dárkkuhitgo:
harm » farm (Viiddit ozu)
resolve. » resolved. (Viiddit ozu)
revolves. » resolves. (Viiddit ozu), resolved. (Viiddit ozu), evolved. (Viiddit ozu)
Čájehuvvojit 1 - 20 oktiibuot 142 bohtosis ohcui harm is (((((evolvedsddddsds. OR resolve.) OR resolve.) OR revolves.) OR involved.) OR involves.)', ohcanáigi: 0,10s Aiddostahte ozu
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl Dahkki Elham Mazarei (4508746)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.

    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. Dahkki Diana M. Hendrickx (1507435)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB).

    Claudin-5 is involved in one of the main proteins that control the blood-brain barrier (BBB). Dahkki Zhizhong Wang (838758)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: